ReviewProceedings of the American Thoracic Society2007
Patient-reported outcomes in cystic fibrosis.
Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- Short-acting inhaled bronchodilators for cystic fibrosis.The Cochrane database of systematic reviews · 2022Pooled it
- Long-acting inhaled bronchodilators for cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Airway clearance physiotherapy and health-related quality of life in cystic fibrosis.PloS one · 2022Trial
- Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.PloS one · 2020Trial
- Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.The New England journal of medicine · 2017Trial
- Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia.BMC pulmonary medicine · 2016Trial
- Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.Health and quality of life outcomes · 2015Trial
- Quality of life is associated with physical activity and fitness in cystic fibrosis.BMC pulmonary medicine · 2014Trial
- Trial
- Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.Chest · 2009Trial
- Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.American journal of respiratory and critical care medicine · 2008Trial
- The Validity and Reliability of the Turkish Version of the AWESCORE Test.Turkish archives of pediatrics · 2025Article
- Symptoms and quality of life in adults with cystic fibrosis: A cross-sectional analysis of the InSPIRe:CF trial.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Current cough and sputum assessed by the cough and sputum assessment-questionnaire (CASA-Q) is associated with quality of life impairment in cystic fibrosis.BMC pulmonary medicine · 2023Article
- Review
- FACTORS ASSOCIATED TO QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2020Article
- Article
- Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis.Mediators of inflammation · 2019Article
- Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up.European journal of pediatrics · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcome measures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.